

December 25, 2018

Advances and Controversies in the Biology and Therapy of Acute Leukemia and Myelodysplasia

Thursday-Friday, April 11-12, 2019 – Newport Beach, CA

Thursday April 11, 2019

1:00 **Introduction**
Jacob M. Rowe, MD, Co-Chairman

Session 1: Novel Strategies in ALL

Moderators: *Adolfo A. Ferrando, MD, PhD*
 Wendy Stock, MD

1:05-1:20 **How advanced are we in targeting novel subsets of ALL, other than Ph-positive or Ph-like?**
Charles G. Mullighan, MD

1:20-1:30 Discussion

1:30-1:45 **What is the best approach for relapsed ALL?**
Daniel J. DeAngelo, MD, PhD

1:45-1:55 Discussion

1:55-2:10 **Can Ph-like ALL be effectively targeted?**
Elizabeth A. Raetz, MD

2:10-2:20 Discussion

2:20-2:35 **Treatment of T-cell malignancies with gene edited CAR-T**
John F. DiPersio, MD, PhD

2:35-2:45 Discussion

2:45-3:05 Break

Session 2: Advances in Myelodysplasia

Moderators: *Eric Padron, MD*
 Rafael Bejar, MD, PhD

3:05-3:20 **Does mutational burden add to other prognostic factors in MDS?**
Aziz Nazha, MD

3:20-3:30 Discussion

3:30-3:45 **What is the role of the microenvironment in MDS?**

Laura M. Calvi, MD

3:45-3:55 Discussion

3:55-4:10 **Which are the most promising novel agents in MDS?**

Thomas Prebet, MD, PhD

4:10-4:20 Discussion

4:20-4:35 **How important is early therapy in MDS?**

David P. Steensma, MD

4:35-4:45 Discussion

4:45-5:00 **Young Investigator Award**

5:00-6:00 **Poster Session/Reception**

Friday April 12, 2019

7:00–7:40 **Registration and Breakfast**

7:45–7:50 **Introduction**
Jacob M. Rowe, MD, Co-Chairman

Session 1: Basic Biology

Moderators: *Marshall A. Lichtman, MD*
 Timothy A. Graubert, MD

7:50–8:05 **Can we selectively target human leukemia stem cells?**
Craig T. Jordan, PhD

8:05–8:15 Discussion

8:15–8:30 **How close are we to early diagnosis of AML?**
Liran Shlush, MD, PhD

8:30–8:40 Discussion

8:40–8:55 **What do novel molecular genetic abnormalities tell us about pathogenesis of AML?**
Jeffrey W. Tyner, PhD

8:55–9:05 Discussion

9:05–9:25 Break

Session 2: Therapy of Induction, Post-remission and Relapse

Moderators: *Elihu H. Estey, MD*
 Richard M. Stone, MD

9:30–9:45 **Is it time to change dose and schedule for AML consolidation?**
Richard A. Larson, MD

9:45–9:55 Discussion

9:55–10:10 **Beyond midostaurin, which are the most promising FLT3 inhibitors in AML?**
Eunice Wang, MD

10:10–10:20 Discussion

10:20–10:35 **How close are we to CAR-T therapy for AML?**
Saar Gill, MD, PhD

10:35–10:45 Discussion

10:45–11:00 **What is the best treatment for a fit patient >75 years with AML?**
Selina M. Luger, MD

- 11:00–11:10 Discussion
- 11:10–11:25 **Which novel agents hold the greatest promise in AML?**
Courtney D. DiNardo, MD
- 11:25–11:35 Discussion
- 11:35–12:35 Lunch

Session 3: Bone Marrow Transplantation

Moderators: *Armand Keating, MD*
 Daniel J. Weisdorf, MD

- 12:40–12:55 **Who should be transplanted at diagnosis, without any pre-transplant therapy?**
Nelson JA Chao, MD
- 12:55–1:05 Discussion
- 1:05–1:20 **Is there a role for maintenance therapy post-transplantation?**
Frederick R. Appelbaum, MD
- 1:20–1:30 Discussion
- 1:30–1:45 **Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation?**
Richard J. Jones, MD
- 1:45–1:55 Discussion
- 1:55–2:10 **What have we learned from transplanting older patients?**
Karen K. Ballen, MD
- 2:10–2:20 Discussion
- 2:20–2:40 Break

Session 4: Supportive Care and Perspective

Moderators: *Kenneth Kaushansky, MD*
 Nancy Berliner, MD

- 2:45–3:00 **Are we making major progress in the management of GvHD?**
James LM Ferrara, MD, DSc
- 3:00–3:10 Discussion

3:10–3:20	<u>Ernest Beutler Memorial Lecture</u> Introduction of Timothy Ley, MD <i>David P. Steensma, MD</i>
3:20–3:50	Genomics in AML <i>Timothy J. Ley, MD</i>
3:50–3:55	Discussion
3:55–4:00	Concluding remarks and close <i>Martin S. Tallman, MD, Co-Chairman</i>